RxDoctor Payments Data

Audrea Sherman, APRN

Family · Silver Spring, MDNPI 1114400942

Payments from drug & device makers

$1,975in general payments, 2019–2025

Across 91 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$860
  • AbbVie$151
  • Boston Scientific$144
  • Vertos Medical, Inc.$139
  • Scilex Pharmaceuticals Inc.$117
  • Zealand Pharma US, Inc.$86
  • plus $477 from 12 others

What the payments were for

  • Food & beverage$1,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,975 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$125,954
Medicare patients
400
Services billed
1,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen11$35,508
OxycontinOxycodone Hcl64$27,591
RelistorMethylnaltrexone Bromide12$27,509
Xtampza ErOxycodone Myristate47$23,186
BelbucaBuprenorphine Hcl16$13,886
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen420$12,731
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl44$12,445
Lidocaine70$6,552
MovantikNaloxegol Oxalate14$6,425
Oxycodone Hcl393$6,193
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen166$4,952
Morphine Sulfate ErMorphine Sulfate201$4,110
Fentanyl32$3,607
Pregabalin127$3,256
Gabapentin221$2,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$860$37,07263 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$35$27,50912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →